Oral Delivery of Large Molecules

About Us

Management Team

Management Team

Dr. Roger Garceau - Interim CEO

Dr. Garceau has more than 30 years of broad pharmaceutical industry experience and has served as a director since March 2016 and as our Chief Development Advisor since December 2016. Prior to joining Entera, Dr. Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. since December 2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals was acquired by Shire plc. Previously, Dr. Garceau has also served in several managerial positions with NPS Pharmaceuticals, Inc., Sanofi-aventis and Pharmacia Corporation. Dr Garceau has been a non-executive director of Enterome SA since December 2016. He is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. Dr. Garceau holds B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School.

Dr. Phillip Schwartz President of R&D and Executive Vice President

Dr. Schwartz has more than twenty years of biotech and pharmaceutical industry experience. He has served as CEO and director of the board of director of Entera since its inception in 2010. Previously he held multiple positions in medical affairs, business development and clinical trial development at Serono and served as manager of clinical affairs at Endo Pharmaceuticals. He served as consultant to more than 20 large biotech and pharmaceutical companies and a number of venture capital firms. Dr Schwartz has multiple publications in tier one peer reviewed journals and has presented papers at numerous international conferences. Dr. Schwartz completed his BA in psychology and architecture at Columbia University. He then studied and worked in neurobiology with Nobel Laureate Professor Torsten Wiesel of the Rockefeller University. After completing his project, Dr. Schwartz studied immunology with Professor Irun Cohen at the Weizmann Institute, receiving his MSc. in 1991. In 1997 Dr. Schwartz received his Ph.D. in neurobiology/development/oncology from Harvard Medical School.

Dr. Hillel Galitzer – COO

Dr. Galitzer has more than ten years of experience in medical research and molecular biology and was mentored by two world renowned researchers in the field of PTH and calcium regulation. He has served as COO since February 2014, and on partial time as Director of Scientific Development since July 2010. Between August 2010 and February 2014 Dr. Galitzer was an analyst and COO for Hadasit Bio Holdings Ltd., a publicly traded company on the TASE and OTC markets. Dr. Galitzer is the co-founder and Chief Operating Officer of Optivasive Inc. He has written numerous publications in tier one peer reviewed articles and has lectured and presented in international conferences and universities. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, and his M.B.A. from Bar-Ilan University in Israel.

Dr. Arthur Santora - CMO

Dr. Santora has more than 30 years of experience in the biotech industry. He has spent the majority of his career in the clinical research team at Merck, where he was the lead clinical research physician responsible for much of the clinical development of Fosamax® (alendronate sodium), one of the world's most prescribed osteoporosis treatments. Dr. Santora was closely involved in the clinical development of Merck’s once-weekly Fosamax Plus D (alendronate sodium/ vitamin D3 combination tablets), the first drug/vitamin combination tablet in the US. His position when he retired from Merck in 2017 was as Scientific Associate Vice President of Clinical Research, where he was directly responsible for the technical and scientific support for all clinical research of Fosamax/Fosamax plus D and contributed to the development of many other osteoporosis and endocrine marketed and investigational drugs. Dr. Santora started his career at the FDA after completing an Endocrinology and Metabolism fellowship at the NIH Clinical Center in Bethesda, MD. He received an M.D. and Ph.D. in biochemistry from Emory University in Atlanta.

Dana Yaacov-Garbeli, CPA, - Israel CFO.

Mrs. Yaacov-Garbeli brings over 11 years of finance and accounting experience, including more than 9 years of experience at a Big-4 accounting firm, PwC. She has expertise in financial planning, operations, management, and strategy with extensive experience in external and internal audit for public multinational clients under US GAAP, IFRS and PCAOB standards. She is currently a Partner at A2Z-Finance, where she served as an outsourced CFO to both private and publicly traded companies and provided additional consulting and accounting services.  At PwC she served as the Lead Senior Manager on audits of both public and privately held multi-location companies in Israel, US and Europe, mainly in pharmaceuticals, biotech, holdings, industrial products, retail and high-tech sectors.  She received an MBA from The College of Management Academic Studies in Israel, with a concentration in financial management, and is a Certified Public Accountant. 

Jonathan Lieber US CFO

Jonathan Lieber has almost 30 years of experience in financial and executive management at emerging and growth-stage life sciences companies, as well as in investment banking. As a chief financial officer, Mr. Lieber has helped raise more than $300 million of equity and debt in public and private offerings, including a $110 million initial public offering at Altus Pharmaceuticals, and led myriad strategic and business development transactions, including the successful sale of Xcellerex to GE Healthcare. Mr. Lieber currently serves as Managing Director, New England for Danforth Advisors, a consulting firm providing operational accounting and finance support, together with CFO services, for private and public life science companies. Previously, he served as CFO of Histogenics Corporation, a publicly traded cell therapy company developing products for the orthopedics market. Mr. Lieber also served as CFO of Metamark Genetics, Inc., and CFO and Treasurer of Repligen Corporation. Previously, Mr. Lieber worked as an investment banker for almost 10 years, during which time he originated and executed on numerous corporate financings and M&A transactions at SG Cowen and Salomon Brothers. Mr. Lieber earned a B.S. in Business Administration and Finance from Boston University and was awarded a M.B.A. in Finance from New York University Stern School of Business.